China transitions from generics leader to innovation hub, contributing ~30% to global R&D pipeline.
Rapid advancements in high-end FDF reflect policy and investment shifts.
Innovation Highlights
- Biosimilars Boom: Numerous mAb biosimilars launched, expanding sterile capabilities.
- Complex Generics: Progress in controlled-release and specialty products via consistency evaluations.
- Novel Therapies: ADCs, GLP-1 analogs, and advanced injectables through collaborations.
- Policy Support: Reforms encourage differentiation and global competitiveness.
China's innovators deliver affordable advanced FDF therapies worldwide.